Obsidian Therapeutics scores $49.5 mln Series A

Cambridge, Massachusetts-based Obsidian Therapeutics Inc, a biotechnology company, has closed $49.5 million in Series A financing. GV led the round with participation from Atlas Venture, Takeda Ventures Inc, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments and ShangPharma Investment Group. In addition to the funding, Obsidian has named Dr. Michael Gilman as CEO.

ManagersNorth AmericaUSHealthcareBriefs